EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Holdings Cut by Two Sigma Advisers LP

Two Sigma Advisers LP lowered its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 37.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 104,500 shares of the company's stock after selling 62,000 shares during the quarter. Two Sigma Advisers LP owned approximately 0.15% of EyePoint Pharmaceuticals worth $779,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Suvretta Capital Management LLC increased its holdings in EyePoint Pharmaceuticals by 31.1% in the fourth quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock valued at $50,534,000 after buying an additional 1,607,268 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in EyePoint Pharmaceuticals by 51.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after purchasing an additional 1,958,580 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 3.1% in the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company's stock valued at $30,825,000 after buying an additional 125,519 shares during the period. Vanguard Group Inc. grew its position in shares of EyePoint Pharmaceuticals by 24.8% during the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock valued at $28,334,000 after buying an additional 755,045 shares during the last quarter. Finally, Federated Hermes Inc. raised its stake in EyePoint Pharmaceuticals by 92.7% during the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after acquiring an additional 1,783,765 shares during the period. Institutional investors own 99.41% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on EYPT. Chardan Capital reduced their price objective on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, May 29th. Wall Street Zen raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Finally, Mizuho dropped their price target on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research note on Friday, May 16th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $25.38.

EyePoint Pharmaceuticals Price Performance

Shares of EyePoint Pharmaceuticals stock traded down $0.01 on Thursday, hitting $8.19. The company had a trading volume of 251,376 shares, compared to its average volume of 819,352. The company has a market cap of $563.49 million, a PE ratio of -4.10 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $13.99. The business has a 50-day simple moving average of $5.98 and a 200-day simple moving average of $6.93.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, meeting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The business had revenue of $24.50 million during the quarter, compared to analysts' expectations of $8.84 million. On average, equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.